Your heartHealthy livingFor professionalsResearchHow you can helpAbout us

Revolutionising heart valve replacements with nanotechnology

Research directory


Revolutionising heart valve replacements with nanotechnology

Dr Richard Tan, University of Sydney

2023 Vanguard Grant - Two Year

Years funded: 2024 - 2025

Aortic stenosis, the most prevalent heart valve disease affecting 2-7% of those over 65, has a grim 3-year survival rate of <30% if untreated. Transcatheter aortic valve implantation (TAVI), a minimally invasive procedure that replaces stenotic valves with new leaflets, is an increasingly common solution following success in older and high-risk patients. TAVI allows earlier intervention with greater benefits to quality of life. However, extending TAVI’s benefits to a wider range of patients, including younger and low-risk groups, requires valve leaflets that last longer in the body. Bovine/porcine pericardium leaflets, which are currently the only materials compatible with TAVI, are susceptible to accelerated mechanical degradation and calcification, limiting their lifespan to 5-10 years. This project will develop a nanoparticle therapy which can coat pericardium leaflets prior to and/or after TAVI to improve their biological resilience to degradation and calcification, helping to extend TAVI’s benefits to larger patient cohorts.

Last updated12 March 2024